Paxlovid - Antiviral Medication for COVID-19
Paxlovid FAQ
What is a paxlovid fact sheet?
This Fact Sheet contains information to help you understand the risks and benefits of taking the PAXLOVID you have received or may receive. This Fact Sheet also contains information about how to take PAXLOVID and how to report side effects or problems with the appearance or packaging of PAXLOVID. What is COVID-19?
What is paxlovid used for?
PAXLOVID is used to treat COVID-19 in adults who are at increased risk of progression to hospitalisation or death. For more information, see Section 1. Why am I taking PAXLOVID? in the full CMI.
How effective is paxlovid?
Efficacy in participants at high risk of progressing to severe COVID-19 illness (EPIC-HR). The efficacy of Paxlovid is based on the analysis of EPIC-HR, a Phase 2/3, randomised, double-blind, placebo-controlled study in non-hospitalised symptomatic adult participants with a confirmed diagnosis of SARS-CoV-2 infection.
How do I take paxlovid®?
• Paxlovid® consists of 2 medications: nirmatrelvir and ritonavir. • Take 2 pink tablets of nirmatrelvir with 1 white tablet of ritonavir by mouth twice a day, in the morning and at bedtime, for 5 days. Take all 3 tablets at the same time • You must always take the nirmatrelvir tablets at the same time as the ritonavir tablet.
Paxlovid References
If you want to know more about Paxlovid, consider exploring links below:
What Is Paxlovid
- https://www.yalemedicine.org/news/13-things-to-know-paxlovid-covid-19
- https://www.drugs.com/paxlovid.html
- https://www.wired.com/story/what-is-paxlovid/
- https://www.tga.gov.au/resources/auspmd/paxlovid
- https://www1.racgp.org.au/newsgp/clinical/study-questions-paxlovid-s-covid-19-usefulness
- https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/
- https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults
- https://www.factcheck.org/2022/05/scicheck-qa-on-paxlovid-pfizers-covid-19-oral-antiviral/
- https://www.pfizer.com/news/press-release/press-release-detail/pfizers-paxlovidtm-receives-fda-approval-adult-patients
- https://www.chop.edu/paxlovid-covid-19-what-you-need-know
Paxlovid Information
- https://www.health.wa.gov.au/~/media/Corp/Documents/Health-for/Infectious-disease/COVID19/Treatment/COVID19-PAXLOVID-Patient-information.pdf
- https://www.nps.org.au/medicine-finder/paxlovid
- https://labeling.pfizer.com/ShowLabeling.aspx?id=16670
- https://www.cec.health.nsw.gov.au/__data/assets/pdf_file/0020/702821/Information-for-patients-family-and-carers-nirmatrelvir-and-ritonavir.PDF
- https://www.racgp.org.au/clinical-resources/covid-19-resources/clinical-care/oral-antiviral-treatments-for-covid-19-br-prescrib/paxlovid-nirmatrelvir-plus-ritonavir
- https://www.sahealth.sa.gov.au/wps/wcm/connect/51e4791c-98c8-4a60-aed5-e355dadf7b47/COVID-19+Treatment+Fact+Sheet+-+Paxlovid+-+Patients+FINAL+June+2022.pdf?MOD=AJPERES